Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indoline SCHEMBL29360339 | 0.97 | — | — | |
| Indoline SCHEMBL5629 | 0.97 | — | — | |
| Indoline SCHEMBL10723456 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL1587228 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL8297160 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL23295083 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL11401846 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL8194348 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL4903255 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 | |
| Indoline SCHEMBL6872936 | 0.95 | HTR2C (0.50) | HTR2CDRD2DRD4PDPK1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115209869-A | Transparent colored cosmetic composition capable of automatically changing color under ultraviolet irradiation | 因特科股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-108033906-B | Preparation method of silodosin intermediate | 常州瑞明药业有限公司 | 2021-07-06 | — | — | CN | claimed |
| US-6489475-B2 | ENZYME INHIBITOR; LIPOPEROXIDATION INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 2002-12-03 | — | — | US | claimed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2001095903-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| US-12618346-B2 | Thermal storage materials and applications thereof | BRANDEIS UNIVERSITY (US) | 2026-05-05 | — | — | US | disclosed |
| CN-115209869-B | Transparent color cosmetic composition capable of automatically changing color under ultraviolet irradiation | 因特科股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240103005-A1 | N-ACRYLOYLINDOLES AND METHODS OF USE | VERSITECH LIMITED (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-117126096-A | N-acryloylindoles and methods of use | 香港大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-111763168-B | Preparation method of silodosin | 滁州市庆云医药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-4544662-A | ALDOSE REDUCTASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES (GB) | 1985-10-01 | — | — | US | disclosed |
| US-4523021-A | ANTIDIABETIC AND ANTIGLACTOSEMIA AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| EP-0065407-B1 | PHARMACEUTICAL SPIRO-SUCCINIMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-13 | — | — | EP | disclosed |
| US-4478847-A | ALDOSE REDUCTASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0094184-A1 | Indoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-11-16 | — | — | EP | disclosed |
| EP-0065407-A2 | Pharmaceutical spiro-succinimide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030888-B2 | Himastatin derivatives, and processes of preparation thereof, and uses thereof | PCSK9, HMGCR, PCSK7 | HTR2C 2919/4885DRD2 4541/4885DRD4 3995/4885 |
| US-20240103005-A1 | N-ACRYLOYLINDOLES AND METHODS OF USE | NAT1, DDIT3, ACR | HTR2C 340/4885DRD2 837/4885DRD4 1388/4885 |
| US-12618346-B2 | Thermal storage materials and applications thereof | CPT2, TRPA1, ACACA | HTR2C 1258/4885DRD2 1348/4885DRD4 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.